Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- ACC Practice Made Perfect: Acing the Transition: From FIT to FacultyIn this episode, Drs. Laura Onderko, Aditya Bharadwaj, and David Winchester explore the transition from fellowship to faculty.
- ACC CardiaCast: GDMT Will Not Delay HF TreatmentIn this episode, Michelle M. Kittleson, MD, PhD, FACC, and Estefania Oliveros Soles, MD, MSc, FACC discuss challenges in heart failure (HF) care, focusing on utilization of guideline-directed medical therapy (GDMT). Learners will hear tips on how to add and maximize GDMT in patients with HF.
- ACC-Hosted UN Side Events Focus on Opportunities to Address Global Burden of NCDsWith the fourth High-level United Nations General Assembly (UNGA) meeting taking place in New York the week of Sept. 22, the ACC hosted two separate side events tied into the overall theme of "Equity and Integration: Transforming Lives and Livelihoods Through Leadership and Action on Noncommunicable Diseases (NCDs) and the Promotion of Mental Health and […]
- New Global Burden of CVD Report Shows Wide Variation Among CountriesCardiovascular disease remains the leading cause of disease burden, causing one in three deaths worldwide, according to the latest Global Burden of Disease study report published Sept. 24 in JACC and presented during a special side event as part of the 80th Session of the United Nations General Assembly in New York.
- OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC VersionsOral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published Sept. 17 in NEJM.